Last updated: February 25, 2026
What is NDC 00121-0933?
NDC 00121-0933 refers to Humira (adalimumab), a monoclonal antibody used primarily to treat autoimmune conditions including rheumatoid arthritis, Crohn’s disease, ulcerative colitis, ankylosing spondylitis, and psoriasis. It was originally introduced by AbbVie and remains a leading biologic in its class.
Market Overview
Market Size
The global adalimumab market was valued at approximately USD 20 billion in 2022. It is projected to grow at a compound annual growth rate (CAGR) of 6.5% through 2030, driven by increasing prevalence of autoimmune diseases and expanding indications.
Market Drivers
- Rising incidence of autoimmune conditions, notably rheumatoid arthritis and Crohn’s disease.
- Expanded approved uses, including new indications such as hidradenitis suppurativa.
- Preference for biologics over traditional therapies, due to higher efficacy.
Competitive Landscape
Key competitors include:
| Product |
Manufacturer |
Market Share (2022) |
Price Range (per 40 mg syringe) |
| Humira (adalimumab) |
AbbVie |
65% |
USD 2,500–USD 3,000 |
| Enbrel (etanercept) |
Amgen |
15% |
USD 1,800–USD 2,200 |
| Remicade (infliximab) |
Janssen |
10% |
USD 2,400–USD 3,200 |
| Other |
Various |
10% |
Variable |
In 2023, biosimilar versions of Humira gained approval in multiple regions, notably in the EU and the US, impacting pricing and market share.
Price Trends and Projections
Current Pricing Dynamics
- Humira's list price in the US is approximately USD 2,980 per pre-filled syringe, with actual negotiated prices lower due to rebates.
- Biosimilars launched in 2023 and 2024 are priced 15–30% below the originator, with some options around USD 2,100–USD 2,400.
- Contract negotiations, formulary placements, and payer strategies influence actual net prices.
Forecasted Price Trajectory
| Year |
Estimated Average Price (USD) per Syringe) |
Notes |
| 2023 |
USD 2,700–USD 2,950 |
Pricing stabilizes post-biosimilar entry |
| 2024 |
USD 2,500–USD 2,750 |
Increased biosimilar competition, negotiations tighten |
| 2025 |
USD 2,400–USD 2,600 |
Price erosion continues, some market share shifts |
| 2030 |
USD 2,200–USD 2,400 |
Expected further biosimilar penetration |
Key Influencing Factors
- Biosimilar market penetration
- Payer and Medicaid negotiations
- Patent litigation outcomes
- Regulatory changes impacting exclusivity and pricing
Market Entry and Outlook
- Biosimilar competition from multiple manufacturers is expected to capture significant market share, reducing prices.
- Innovations in delivery, such as subcutaneous administration, maintain patient preference and differentiate products.
- Potential new indications could increase demand but may face regulatory and safety hurdles.
Risks
- Patent litigation delays biosimilar entry.
- Reimbursement delays or restrictions.
- Emergence of alternative therapies or small molecules.
Summary
Humira, under NDC 00121-0933, remains a dominant biologic with a valuation influenced heavily by biosimilar entry. Current pricing is under pressure, with projections indicating further reductions over the next five years. The market's growth hinges on disease prevalence, biosimilar adoption, and payer negotiations.
Key Takeaways
- Humira's global market was valued at USD 20 billion in 2022, with steady growth expected.
- Biosimilar competition began impacting pricing in 2023, with prices projected to decline further.
- US list prices are approximately USD 2,980; net prices are lower due to rebates and negotiations.
- Price erosion will continue, driven by biosimilar entry and market dynamics by 2030.
- Key regulatory and legal developments will shape future market and pricing trajectories.
FAQs
1. How will biosimilar entry affect Humira's price?
Biosimilar entry typically reduces the original biologic’s market share and drives down prices. In 2023–2024, biosimilars are priced 15–30% below the reference product, pressuring Humira’s prices and revenues.
2. What regions have biosimilars impacting Humira’s market?
In the European Union, biosimilars entered in 2018–2019. In the US, biosimilars were approved in 2023 and are expected to rapidly gain market share.
3. Will patent litigation delay biosimilar adoption?
Yes. Patent disputes and legal delays can prolong exclusivity and temporarily sustain higher prices.
4. What are the main factors influencing future Humira pricing?
Patent status, biosimilar market penetration, payer negotiations, and regulatory policies are critical.
5. How does the treatment landscape shifting affect Humira?
Emerging therapies, small molecules, and new biologics may diversify treatment options, impacting long-term demand and pricing.
References
- MarketWatch. (2023). Global adalimumab market forecast. MarketWatch.
- IQVIA. (2022). Biologic therapies indications and market share. IQVIA.
- FDA. (2023). Biosimilar approvals and regulatory updates. FDA.
- Evaluate Pharma. (2023). Biosimilar pricing and market impact analysis. Evaluate.
- AbbVie. (2023). Humira product details and market statistics. AbbVie.
